Drug intelligence / Profile preview

chenopodium botrys pollen

Development stage
Unknown
Lead developer
Ares Life Sciences
Modality
Vaccines & Immunotherapeutics
Administration
Subcutaneous, Intradermal, Topical
01

Overview

Chenopodium botrys pollen is an allergenic extract derived from the pollen of the Jerusalem oak goosefoot plant (also known as Dysphania botrys). It is utilized in clinical practice for both the diagnosis and treatment of Type I hypersensitivity reactions, such as allergic rhinitis and asthma, in individuals sensitized to this specific weed pollen. As a diagnostic tool, it is used in skin prick or intradermal testing to identify specific IgE-mediated sensitivity. As a therapeutic agent, it is employed in allergen immunotherapy (desensitization), where repeated exposure to increasing doses of the allergen induces immunological tolerance. This process typically involves a shift from a Th2-dominated allergic response to a Th1/Treg-mediated response, characterized by the production of blocking antibodies (IgG4) and a reduction in allergen-specific IgE levels.

Brand names
Allergenic Extract Jerusalem Oak
Other names
Jerusalem oak goosefoot pollenDysphania botrys pollenFeather geranium pollen
02

Targets

A. annua-specific IgE (Artemisia annua-specific immunoglobulin E)

Beyond the preview

Go deeper on chenopodium botrys pollen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on chenopodium botrys pollen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call